EQRx, Inc. engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor, and Sugemalimab, an anti-programmed death-ligand 1 antibody.
| Market Cap | 879.18 Million | Shares Outstanding | 488.433 Million | Avg 30-day Volume | 2.54 Million |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.36 |
| Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -99.262 Million |
| Price to Book Value | 1.4587 | Operating Margin | 0.0 | Enterprise Value | 527.199 Million |
| Current Ratio | 43.036 | EPS Growth | 0.829 | Quick Ratio | 42.338 |
| 1 Yr BETA | 1.1976 | 52-week High/Low | 6.05 / 1.72 | Profit Margin | 0.0 |
| Operating Cash Flow Growth | 24.151 | Altman Z-Score | 6.8526 | Free Cash Flow to Firm | 22.641 Million |
| Earnings Report | 2023-05-03 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
AH EQUITY PARTNERS LSV I, L.L.C. ANDREESSEN HOROWITZ LSV FUND I, L.P. ANDREESSEN HOROWITZ LSV FUND I-B, L.P. ANDREESSEN HOROWITZ LSV FUND I-Q, L.P. AH EQUITY PARTNERS LSV II, L.L.C. ANDREESSEN HOROWITZ LSV FUND II, L.P. ANDREESSEN HOROWITZ LSV FUND II-B, L.P. |
|
53,076,421 | 2023-01-01 | 1 |
|
21,934 | 2023-01-01 | 1 | |
|
86,344 | 2023-01-01 | 1 | |
|
43,172 | 2023-01-01 | 1 | |
|
BORISY ALEXIS EXECUTIVE CHAIRMAN |
|
2,892,491 | 2023-01-01 | 1 |
|
HEDRICK ERIC CHIEF PHYSICIAN EXECUTIVE |
|
103,612 | 2023-01-01 | 1 |
|
4,754,740 | 2023-01-01 | 1 | |
|
107,929 | 2023-01-01 | 1 | |
|
6,618,825 | 2023-01-01 | 1 | |
|
NALLICHERI MELANIE CHIEF EXECUTIVE OFFICER |
|
1,571,443 | 2023-01-01 | 1 |
|
AH EQUITY PARTNERS BIO II, L.L.C. |
|
53,076,421 | 2023-01-01 | 1 |
|
RUBIN JAMI CHIEF FINANCIAL OFFICER |
|
302,203 | 2023-01-01 | 1 |
|
CIARIMBOLI DINA GENERAL COUNSEL AND SECRETARY |
|
43,172 | 2023-01-01 | 1 |
|
0 | 2022-09-30 | 1 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| EQRX INC EQRX | 2023-03-24 22:15:03 UTC | 3.1639 | 1.6561 | 550000 |
| EQRX INC EQRX | 2023-03-24 21:45:03 UTC | 3.1639 | 1.6561 | 550000 |
| EQRX INC EQRX | 2023-03-24 21:15:03 UTC | 3.1639 | 1.6561 | 550000 |
| EQRX INC EQRX | 2023-03-24 20:45:03 UTC | 3.1968 | 1.6232 | 550000 |
| EQRX INC EQRX | 2023-03-24 20:15:04 UTC | 3.1968 | 1.6232 | 550000 |
| EQRX INC EQRX | 2023-03-24 19:45:03 UTC | 3.1968 | 1.6232 | 550000 |
| EQRX INC EQRX | 2023-03-24 19:15:04 UTC | 3.1968 | 1.6232 | 550000 |
| EQRX INC EQRX | 2023-03-24 18:45:04 UTC | 3.1968 | 1.6232 | 550000 |
| EQRX INC EQRX | 2023-03-24 18:15:03 UTC | 3.1968 | 1.6232 | 550000 |
| EQRX INC EQRX | 2023-03-24 17:45:03 UTC | 3.1968 | 1.6232 | 550000 |
| EQRX INC EQRX | 2023-03-24 17:15:03 UTC | 3.1968 | 1.6232 | 550000 |
| EQRX INC EQRX | 2023-03-24 16:45:03 UTC | 3.1988 | 1.6212 | 550000 |
| EQRX INC EQRX | 2023-03-24 16:15:03 UTC | 3.1988 | 1.6212 | 550000 |
| EQRX INC EQRX | 2023-03-24 15:45:03 UTC | 3.1988 | 1.6212 | 550000 |
| EQRX INC EQRX | 2023-03-24 15:15:03 UTC | 3.1988 | 1.6212 | 550000 |
| EQRX INC EQRX | 2023-03-24 14:45:03 UTC | 3.1988 | 1.6212 | 550000 |
| EQRX INC EQRX | 2023-03-24 14:15:03 UTC | 3.1988 | 1.6212 | 550000 |
| EQRX INC EQRX | 2023-03-24 13:45:03 UTC | 2.8763 | 1.6937 | 550000 |
| EQRX INC EQRX | 2023-03-24 13:15:04 UTC | 2.8763 | 1.6937 | 550000 |
| EQRX INC EQRX | 2023-03-24 12:45:03 UTC | 2.8763 | 1.6937 | 550000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|---|---|---|---|
| Brinker Capital Destinations Trust- Destinations Multi Strategy Alternatives Fund | EQRX | -446038.0 shares, $-1677102.88 | 2022-11-30 | N-PORT |
| Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | EQRX | -41800.0 shares, $-102828.0 | 2022-12-31 | N-PORT |
